What is a vascular occlusion from filler, and what are the warning signs?

What happens in a vascular occlusion

The face is supplied by a network of arteries that run just under the skin and, in places, deep against the bone. If a needle or cannula tip is inside one of them when the plunger is pressed, filler enters the artery and is carried downstream until it lodges and blocks the flow. A large bolus placed next to an artery can also compress it. Either way the skin that artery feeds is suddenly short of blood, and if nothing is done it begins to die over the following days.

Where the filler lodges decides what is at risk. Most occlusions affect the skin of the lip, the fold beside the nose, or the cheek. The dangerous exception is filler that travels backwards up a branch into the arteries around the eye and from there into the artery that supplies the retina. The FDA lists necrosis (tissue death), vision abnormalities including blindness, and stroke among the serious complications reported after filler was unintentionally injected into a blood vessel.

The survey behind those rates also found that most occlusions resolved without lasting harm, and that is the point of this page. For hyaluronic acid filler there is an antidote, hyaluronidase, and the outcome depends mostly on how quickly the problem is recognized and treated.

The warning signs

The CMAC guideline describes an occlusion of the skin as a sequence. Not every stage appears in every case, and the earlier it is caught the fewer stages there are.

Blanching

The first sign is the skin turning white, because blood has stopped arriving. It can happen the moment filler is injected. It may last only seconds and then seem to recover, or it may persist. Either way, the guideline treats pallor or a dusky appearance as a reason to act at once over the whole affected area, not to wait and see. This is the sign an injector is watching for during treatment, and it is why anesthetic with adrenaline, which whitens skin on its own, is avoided for filler.

Pain out of proportion

Sudden, escalating pain during or shortly after an injection, at the injection site or somewhere else on the face, is not normal and is a reason to stop. Two cautions from the guideline: local anesthetic in the filler can mask the pain, and pain is not always present in the early stages. Its absence does not rule an occlusion out; its presence should never be ignored.

Livedo reticularis

As blood backs up in the small veins around the blocked area, the skin develops a purple, net-like or mottled pattern. In the guideline, it can appear quickly and last 24 to 36 hours ^{(source, verified Nov 2026)}. It is the sign a patient is most likely to notice at home, because it can look at first like an odd bruise. A bruise is a patch; livedo is a lace-like pattern that follows the territory of a vessel.

Delayed capillary refill

Press on the skin, release, and watch the color return. In the guideline, color normally returns in under two seconds, and the check is made on both sides of the face for comparison ^{(source, verified Nov 2026)}. Color that takes longer to come back in the treated area than on the other side of the face suggests the arterial supply is compromised. Brisk refill on bluish skin suggests a venous problem instead, which is less urgent. Tanya checks this before, during and after every filler treatment, as the safety page explains.

Later stages

If the occlusion is not treated, the skin progresses: small pustules typically appear at around 72 hours, and darkening of the skin follows over the next days ^{(source, verified Nov 2026)}. Those stages mean tissue is dying. They are what prompt treatment is meant to prevent.

Changes in vision

An occlusion involving the eye announces itself differently. The expert consensus describes vision loss from a retinal artery occlusion as sudden, usually in one eye, often with no pain, and able to occur within seconds of an injection. Patients have also reported double vision or a drooping eyelid. Any of these during or after a facial injection is an emergency. The consensus states that an occlusion that is maintained for more than 60 to 90 minutes is thought to cause irreversible blindness ^{(source, verified Nov 2026)}, which is why the response has to be immediate rather than careful. The sites that carry this risk are the nose, the glabella and the forehead; the filler safety guide explains why.

How it is treated

The treatment described here is the CMAC guideline’s approach to a hyaluronic acid occlusion of the skin, which is also what the safety page refers to as a rehearsed reversal protocol. Fillers made of other materials cannot be dissolved, which is one reason hyaluronic acid is the usual choice for first treatments and for high-mobility areas.

1. Stop. The injection stops the moment an occlusion is suspected. The patient is told what is happening. The area is photographed or filmed in good light, with capillary refill checked along the line of the suspected artery, so that recovery can be measured against a baseline. The pale area is marked.
2. Hyaluronidase, in quantity. The guideline specifies 1,500 units of hyaluronidase reconstituted in 1 mL of bacteriostatic saline or lidocaine, infiltrated along the course of the affected artery and across the whole pale area, using more than one vial if the area is large ^{(source, verified Nov 2026)}. The instruction is to treat to effect and to focus on covering the whole area rather than on counting units. For comparison, a 2018 expert consensus described doses of 200 to 300 units for an intravascular event, rising to 1,500 units where needed, repeated hourly until the skin recovers ^{(source, verified Nov 2026)}; practice has moved toward the higher, broader dosing.
3. Warmth and massage. The area is warmed and massaged firmly. Both encourage the vessels to dilate and help spread the enzyme through the tissue.
4. Reassess and repeat. Capillary refill is rechecked against the baseline. In the CMAC hyaluronidase guideline, if capillary refill is still slower than three seconds after reassessment, the dose is repeated ^{(source, verified Nov 2026)}. On timing, the 2021 occlusion guideline advised repeating at least hourly, and the group's later hyaluronidase guideline shortened this to re-dosing every 15 to 20 minutes after reassessment ^{(source, verified Nov 2026)}. Dissolving a blockage can take several rounds over several hours, and the patient stays in the clinic for them.
5. Aspirin, with caveats. There is no direct evidence for blood-thinning drugs in filler occlusions. The CMAC guideline nonetheless suggests 300 mg of aspirin at once, then 75 mg daily, where it is safe for the patient, acknowledging that the evidence is extrapolated from heart attack care rather than from filler cases ^{(source, verified Nov 2026)}. Other measures that appear in older protocols, such as nitroglycerin paste and routine steroids, are not recommended by CMAC, though the earlier expert consensus still lists nitroglycerin. Guidelines disagree here, and a patient should expect to see hyaluronidase, heat and massage as the core of treatment.
6. Follow-up. In the guideline, the patient is reviewed the next day even when the skin has fully recovered, and followed until healed if the skin has broken down ^{(source, verified Nov 2026)}. If the skin has broken down, wound care continues for weeks, with antibiotics only when there is an infection to treat.

Hyaluronidase itself carries a small risk of allergic reaction, and the clinic has adrenaline on hand for that reason. In the CMAC hyaluronidase guideline, the risk of anaphylaxis is described as extremely small, lower than the often-quoted 0.1 percent ^{(source, verified Nov 2026)}. In an occlusion, the benefit is not in doubt.

When vision is involved

The sequence changes. Injection stops, vision and pupils are checked, hyaluronidase is given around the injected area, and the patient is sent for emergency ophthalmology care immediately, by ambulance if that is fastest. Measures to lower the pressure in the eye may be started in the meantime. The guideline literature is candid that no treatment has been proven to reverse vision loss from filler, and neither case reports nor animal studies have shown that hyaluronidase restores sight once it is lost ^{(source, verified Nov 2026)}. That candour is the reason so much effort goes into prevention at the high-risk sites, and the reason a patient who notices any visual change should say so at once rather than wait to see whether it passes.

What to watch for after you go home

Most occlusions show themselves in the chair. A few declare themselves over the following hours, and rarely over days. The CMAC guideline expects every patient to leave knowing the warning signs and holding an emergency contact. FDA patient labeling for lip filler puts the same signs under “call your doctor immediately”: changes in your vision; signs of a stroke, such as sudden difficulty speaking, face drooping, numbness or weakness; a white appearance of the skin; unusual pain during or shortly after treatment; and significant pain away from the injection site.

To that list, add the signs above that take a little longer: a purple, mottled or net-like pattern on the skin; a patch that is gray or dusky rather than pink; skin that stays pale when you press and release it compared with the other side; small blisters or pustules appearing two or three days after treatment. Photograph the area in daylight, because color is hard to describe over the phone and a photograph taken an hour apart shows whether something is changing.

What to call about, and how urgently:

• Go to an emergency department now, and call your injector on the way: any change in vision; any sign of a stroke; breathing difficulty.
• Call the direct number now, whatever the hour: skin that has gone white or dusky; a purple net-like pattern; pain that is escalating or out of proportion; pain somewhere other than where you were injected.
• Call the same day: anything on the skin that looks wrong to you and is not clearly a bruise or ordinary swelling. Lip filler swelling, and how to tell it from a warning sign describes what ordinary looks like.

A suspected occlusion needs to be seen in person, urgently, by someone who can treat it. That is why Tanya’s patients leave with a direct number and why the delegating prescriber is reachable during clinic hours, as the safety page sets out.

How the risk is lowered in the first place

Briefly, because the filler safety guide covers this in depth: an injector reduces the chance of an occlusion by knowing where the arteries run in the face in front of them, by placing filler deep on bone where the plan allows, by injecting slowly at low pressure in small amounts, by choosing a cannula where the area and the literature support it, by not relying on aspiration as a safety check, and by having hyaluronidase and a written plan in the room before the first syringe is opened.